452 related articles for article (PubMed ID: 26233698)
1. Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers.
LaBelle CT; Han SC; Bergeron A; Samet JH
J Subst Abuse Treat; 2016 Jan; 60():6-13. PubMed ID: 26233698
[TBL] [Abstract][Full Text] [Related]
2. Training in office-based opioid treatment with buprenorphine in US residency programs: A national survey of residency program directors.
Tesema L; Marshall J; Hathaway R; Pham C; Clarke C; Bergeron G; Yeh J; Soliman M; McCormick D
Subst Abus; 2018; 39(4):434-440. PubMed ID: 29513136
[TBL] [Abstract][Full Text] [Related]
3. Long-term retention in Office Based Opioid Treatment with buprenorphine.
Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
[TBL] [Abstract][Full Text] [Related]
4. Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.
Stein BD; Pacula RL; Gordon AJ; Burns RM; Leslie DL; Sorbero MJ; Bauhoff S; Mandell TW; Dick AW
Milbank Q; 2015 Sep; 93(3):561-83. PubMed ID: 26350930
[TBL] [Abstract][Full Text] [Related]
5. Statement of the American Society Of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction.
Kraus ML; Alford DP; Kotz MM; Levounis P; Mandell TW; Meyer M; Salsitz EA; Wetterau N; Wyatt SA;
J Addict Med; 2011 Dec; 5(4):254-63. PubMed ID: 22042215
[TBL] [Abstract][Full Text] [Related]
6. Challenges in increasing access to buprenorphine treatment for opiate addiction.
West JC; Kosten TR; Wilk J; Svikis D; Triffleman E; Rae DS; Narrow WE; Duffy FF; Regier DA
Am J Addict; 2004; 13 Suppl 1():S8-16. PubMed ID: 15204672
[TBL] [Abstract][Full Text] [Related]
7. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
[No Abstract] [Full Text] [Related]
8. Very early disengagement and subsequent re-engagement in primary care Office Based Opioid Treatment (OBOT) with buprenorphine.
Hui D; Weinstein ZM; Cheng DM; Quinn E; Kim H; Labelle C; Samet JH
J Subst Abuse Treat; 2017 Aug; 79():12-19. PubMed ID: 28673522
[TBL] [Abstract][Full Text] [Related]
9. Using Shared Medical Appointments to Increase Access to Buprenorphine Treatment.
Roll D; Spottswood M; Huang H
J Am Board Fam Med; 2015; 28(5):676-7. PubMed ID: 26355141
[TBL] [Abstract][Full Text] [Related]
10. Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees.
Wen H; Hockenberry JM; Pollack HA
JAMA Netw Open; 2018 Sep; 1(5):e182943. PubMed ID: 30646185
[TBL] [Abstract][Full Text] [Related]
11. Training in Buprenorphine and Office-Based Opioid Treatment: A Survey of Psychiatry Residency Training Programs.
Suzuki J; Ellison TV; Connery HS; Surber C; Renner JA
Acad Psychiatry; 2016 Jun; 40(3):498-502. PubMed ID: 26017618
[TBL] [Abstract][Full Text] [Related]
12. Feasibility of Implementing Shared Medical Appointments (SMAs) for Office-Based Opioid Treatment With Buprenorphine: A Pilot Study.
Suzuki J; Zinser J; Klaiber B; Hannon M; Grassi H; Spinosa M; Ramirez A; Issa M; Chin Feman SP
Subst Abus; 2015; 36(2):166-9. PubMed ID: 25738320
[TBL] [Abstract][Full Text] [Related]
13. Responding to the opioid and overdose crisis with innovative services: The recovery community center office-based opioid treatment (RCC-OBOT) model.
Ashford RD; Brown AM; McDaniel J; Neasbitt J; Sobora C; Riley R; Weinstein L; Laxton A; Kunzelman J; Kampman K; Curtis B
Addict Behav; 2019 Nov; 98():106031. PubMed ID: 31326776
[TBL] [Abstract][Full Text] [Related]
14. Primary care patient characteristics associated with completion of 6-month buprenorphine treatment.
Neumann AM; Blondell RD; Azadfard M; Nathan G; Homish GG
Addict Behav; 2013 Nov; 38(11):2724-8. PubMed ID: 23934003
[TBL] [Abstract][Full Text] [Related]
15. Psychoactive medications and disengagement from office based opioid treatment (obot) with buprenorphine.
Weinstein ZM; Cheng DM; Quinn E; Hui D; Kim H; Gryczynski G; Samet JH
Drug Alcohol Depend; 2017 Jan; 170():9-16. PubMed ID: 27865152
[TBL] [Abstract][Full Text] [Related]
16. Public policy statement on Office-Based Opioid Agonist Treatment (OBOT).
J Addict Dis; 2005; 24(3):153-61. PubMed ID: 16186090
[No Abstract] [Full Text] [Related]
17. Feasibility of collaborative care treatment of opioid use disorders with buprenorphine during pregnancy.
Mittal L; Suzuki J
Subst Abus; 2017; 38(3):261-264. PubMed ID: 26672650
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders.
Carey KJ; Huang W; Linas BP; Tsui JI
J Subst Abuse Treat; 2016 Jul; 66():54-9. PubMed ID: 26988423
[TBL] [Abstract][Full Text] [Related]
19. A comparison of buprenorphine and psychosocial treatment outcomes in psychosocial and medical settings.
Presnall NJ; Wolf DAPS; Brown DS; Beeler-Stinn S; Grucza RA
J Subst Abuse Treat; 2019 Sep; 104():135-143. PubMed ID: 31370977
[TBL] [Abstract][Full Text] [Related]
20. Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine.
Du CX; Shi J; Tetrault JM; Madden LM; Barry DT
Fam Pract; 2022 Mar; 39(2):234-240. PubMed ID: 34893825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
